Phase 2
N=90
Glucose Oxidase as Treatment Against Common Cold
Common Cold
Bottom Line
View on ClinicalTrials.gov: NCT01883440 ↗Enrolled (actual)
90
Serious AEs
0.0%
Results posted
Jan 2016
Primary outcome: Primary: Sum of All Symptoms in Viruspositive Persons — 52; 52; 54; 56 units on a scale — p=<0.037
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Glucose oxidase + glucose (Drug); Saline+glucose (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Krister Tano
- Primary completion
- Aug 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Sum of All Symptoms in Viruspositive Persons |
52; 52; 54; 56; 58; 53 | <0.037 sig |
| PRIMARY Sum of All Symptoms of All Persons That Fullfilled the Study |
42; 42; 44; 42; 45; 39 | 0.381 |
Summary
Glucose oxidase is a hydrogen peroxide producing enzyme, which also is present in honey. Human rhinoviruses are sensitive to the action of hydrogen peroxide, which is documented in laboratory studies.
In the present study we aim to investigate if a nasal spray with glucose oxidase could treat a common cold, when the treatment is started even after the onset of the symptoms. The study is randomized and placebo controlled.
Eligibility Criteria
Inclusion Criteria
- Symptoms of a common cold within the last 24 hours
Exclusion Criteria
- Use of a nasal steroid due to allergy
Data sourced from ClinicalTrials.gov (NCT01883440). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.